# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001610618-20-000025
Filing Date
2020-04-29
Accepted
2020-04-29 16:05:33
Documents
4
Period of Report
2020-04-29
Effectiveness Date
2020-04-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | cdtxdef14a2020.htm | DEF 14A | 623578
2 |  | cdtxlogoa13.jpg | GRAPHIC | 46741
3 |  | proxycard01.jpg | GRAPHIC | 474949
4 |  | proxycard02.jpg | GRAPHIC | 456606
| Complete submission text file | 0001610618-20-000025.txt |  | 1965723

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36912 | Film No.: 20830244
SIC: 2836 Biological Products, (No Diagnostic Substances)